1. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
   G.R. Tundo et al, 2020, Pharmacology & Therapeutics CrossRef
2. Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma
   Motoharu Shibusawa et al, 2022, Case Reports in Hematology CrossRef
3. Management of Peripheral T-Cell Lymphoma in Children and Adolescents Including STAT 3 Mutation Hyper-IgE Syndrome: One Size Does Not Fit All
   Nikila Ravichandran et al, 2022, Journal of Pediatric Hematology/Oncology CrossRef
4. Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
   Pawel Robak et al, 2019, Drugs in R&D CrossRef
5. Evaluation of the clinical characteristics and prognostic factors of gastrointestinal non-Hodgkin lymphoma based on anatomical sites and histological subtype
   Tingxuan Huang et al, 2023, Scandinavian Journal of Gastroenterology CrossRef